Clinical Chemistry Siemens Point of Care - Urinalysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 2309-2315, 2004. First published September 30, 2004; 10.1373/clinchem.2004.034439
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2004.034439v1
50/12/2309    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergmeier, C.
Right arrow Articles by Gross, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergmeier, C.
Right arrow Articles by Gross, W.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2004;50:2309-2315.)
© 2004 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Distribution Spectrum of Paraoxonase Activity in HDL Fractions

Christoph Bergmeier1,a, Rüdiger Siekmeier2 and Werner Gross1

1 Labor für Angewandte Biochemie, Gustav-Embden-Zentrum für Biologische Chemie, Klinikum der J.W. Goethe-Universität, Frankfurt/Main, Germany.
2 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), Bonn, Germany.

aAddress correspondence to this author at: Labor für Angewandte Biochemie, Gustav-Embden-Zentrum für Biologische Chemie, Klinikum der J.W. Goethe-Universität, Atzelbergstrasse 67, 60389 Frankfurt/Main, Germany. Fax 49-69-47874641; e-mail cbergmei{at}stud.uni-frankfurt.de.

Background: Paraoxonase (PON1) associated with HDL can be regarded as a cardio- and vasoprotective enzyme. However, because HDL is not a homogeneous fraction, it is important to investigate in which subgroups of HDL active PON1 is located. It would also be useful to determine density profiles of the HDL apolipoproteins (Apo) E and J.

Methods: We investigated the density range of HDL ({rho} = 1.063–1.256 kg/L) in healthy individuals, using the ultracentrifugation reference method and a newly introduced automated fractionation method. Profiles of PON1 activity and ApoA-I, ApoA-II, ApoE, ApoJ, and cholesterol concentrations were obtained by use of various density gradients.

Results: PON1 activity was highest in the more dense HDL3 and VHDL fractions where PON1 was not dissociated from the particles during centrifugation. The fraction in density range 1.175–1.185 kg/L showed not only the highest PON1 activity, but also the highest specific activity (activity per HDL particle). This fraction was the least-dense fraction containing both ApoE and ApoJ. Only the Q192R polymorphism had an effect on the distribution profile of PON1 activity. In contrast, L55M and the T(–107)C polymorphisms (determined by a novel nonradioactive method) were without effect on the density distribution of PON1 activity.

Conclusion: The HDL3 fraction, which is important in reverse cholesterol transport, also carries the highest PON1 activity.




The following articles in journals at HighWire Press have cited this article:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
W. S. Davidson, R.A. G. D. Silva, S. Chantepie, W. R. Lagor, M. J. Chapman, and A. Kontush
Proteomic Analysis of Defined HDL Subpopulations Reveals Particle-Specific Protein Clusters: Relevance to Antioxidative Function
Arterioscler. Thromb. Vasc. Biol., June 1, 2009; 29(6): 870 - 876.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
P. A. C. McPherson, I. S. Young, B. McKibben, and J. McEneny
High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation
J. Lipid Res., January 1, 2007; 48(1): 86 - 95.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
E. Thomas-Moya, M. Gianotti, A. M. Proenza, and I. Llado
The age-related paraoxonase 1 response is altered by long-term caloric restriction in male and female rats
J. Lipid Res., September 1, 2006; 47(9): 2042 - 2048.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Kontush and M. J. Chapman
Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis
Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. Y. Han, T. Chiba, J. S. Campbell, N. Fausto, M. Chaisson, G. Orasanu, J. Plutzky, and A. Chait
Reciprocal and Coordinate Regulation of Serum Amyloid A Versus Apolipoprotein A-I and Paraoxonase-1 by Inflammation in Murine Hepatocytes
Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1806 - 1813.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al.
The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status
J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke
Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?
J. Lipid Res., March 1, 2005; 46(3): 389 - 403.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.